Iovance Biotherapeutics, Inc. · 3 weeks ago
Senior Cell Therapy Medical Lead - West
United States
Full-time
Onsite
Senior Level, Lead/Staff
12+ years expIovance Biotherapeutics is seeking a Senior Cell Therapy Medical Lead to represent their Medical Affairs team as a TIL cell therapy expert. This role involves engaging with external healthcare stakeholders, collaborating with cross-functional teams, and supporting strategic initiatives in cell therapy and oncology.
BiotechnologyClinical TrialsHealth CareHealth DiagnosticsMedical
Responsibilities
Represent Iovance Medical Affairs as a TIL cell therapy expert in both internal and external venues including the US and Global cross-functional teams, MRB, external consults, clinical sub-teams, and advisory boards / steering committees
Work cross-functionally to support Commercial Quality, Market Access, Clinical Development, and the broader Med Affairs team
Participate in various Medical Affairs cross-functional working groups
Represent Iovance at professional meetings, congresses, and local symposia
Provide high quality clinical input and review of disease strategy plans, slides, manuscripts, educational materials, IIT protocols, steering committee and advisory board meeting objectives, Standard Response Letters, and Commercial Brand plans
Partner with Scientific Communications to develop timely publication strategies and plan, gap analysis, and key messages
Interaction with key stakeholders, as a therapeutic area medical strategy expert: Internal Medical Affairs partners ATC Operations Commercial partners Clinical Science & Clinical Operations Research Alliances Manufacturing Quality Marketing Market Access Regulatory Affairs Project Management Training External Investigators, KOLs Non-physician HCPs Steering Committees Advisory Boards
Travel – 30%
Qualification
Required
Advanced in life sciences or medical discipline
A minimum of 12 or more years of biotech/pharma in a similar role
Prior experience as a surgical Physician Assistant or Nurse Practitioner required, surgical oncology strongly preferred
Expertise in the conduct of clinical trials in hematology/oncology
Excellent analytical skills and solid experience in translating medical, clinical, and surgical information into Medical Affairs strategies that improve tumor procurement quality and manufacturing success
Exceptional oral and written communication skills, with the ability to convey complex scientific and surgical concepts to diverse audiences, including presentations to large groups, facilitation of interactive discussions, and 1:1 interaction with surgeons and other HCPs
Proficiency in critical data review and interpretation, including the ability to evaluate surgical variables impacting product quality and outcomes
Demonstrated customer-focused orientation & credibility with customers
Strong strategic thinking and analytical skills, with the capacity to align scientific initiatives with organizational goals and adapt to evolving industry landscapes
Expertise in leading the development of effective and influential scientific content aligned with the latest advancements in the therapeutic landscape, utilizing PowerPoint for impactful presentations
Knowledge/application of data sources, reports, and tools for the creation of solid plans, including insights into surgical workflows and tumor procurement metrics
Ability and willingness to travel as needed to meet the demands of the role
Company
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
501-1000 employees
H1B Sponsorship
Iovance Biotherapeutics, Inc. has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (12)
2024 (11)
2023 (7)
2022 (7)
2021 (2)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$1.58B2024-02-20Post Ipo Equity· $211M
2023-07-10Post Ipo Equity· $150M
2020-05-27Post Ipo Equity· $603.7M
Leadership Team
Jean-Marc Bellemin
Chief Financial Officer
Cheryl Aranda
Executive Assistant to Chief Medical Officer
Recent News
2025-12-29
2025-12-07
2025-11-11
Company data provided by crunchbase